中国药物警戒 ›› 2025, Vol. 22 ›› Issue (7): 815-818.
DOI: 10.19803/j.1672-8629.20240793

• 安全与合理用药 • 上一篇    下一篇

替罗非班注射液致极重度血小板减少症1例分析

王媛1, 李若柠1, 郭展立1, 张磊1, 李嘉媛1, 冬颖2, 孙建军2,*   

  1. 1内蒙古医科大学药学院,内蒙古 呼和浩特 010107;
    2内蒙古医科大学附属医院药学部,内蒙古 呼和浩特 010050
  • 收稿日期:2024-10-17 出版日期:2025-07-15 发布日期:2025-07-17
  • 通讯作者: *孙建军,男,博士,主任药师,临床药学。E-mail: sunjianjun8840@bjmu.edu.cn
  • 作者简介:王媛,女,硕士,初级药师,临床药学。
  • 基金资助:
    内蒙古自治区卫生健康科技计划项目（202202184）; 内蒙古自治区“草原英才”工程青年创新人才（一层次）支持项目（Q2022084）; 内蒙古医科大学重点项目（YKD2023ZD002）; 内蒙古自治区高等学校科学研究项目（NJZY22623）

One Case of Extremely Severe Thrombocytopenia Caused by Tirofiban Injection

WANG Yuan1, LI Ruoning1, GUO Zhanli1, ZHANG Lei1, LI Jiayuan1, DONG Ying2, SUN Jianjun2,*   

  1. 1College of Pharmacy, Inner Mongolia Medical University, Hohhot Inner Mongolia 010107, China;
    2Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot Inner Mongolia 010050, China
  • Received:2024-10-17 Online:2025-07-15 Published:2025-07-17

PDF (PC)

36

摘要： 目的 探讨替罗非班注射液致极重度血小板减少不良反应的临床特点、处理策略及预后。方法 分析1例替罗非班导致极重度血小板减少症的病例,讨论血小板减少与替罗非班的相关性,并检索国内外相关文献报道,梳理替罗非班诱导血小板减少的发生机制。结果 停止替罗非班给药后及时给予对症处理,血常规指标均正常稳定,病情改善,且预后较好。结论 替罗非班致极重度血小板减少的情况相对罕见,应为患者提供个体化用药监护,并建议临床应用替罗非班过程中监测血小板指标,警惕不良反应的发生。

关键词: 替罗非班, 注射液, 出血, 血小板减少, 经皮冠状动脉介入治疗, 药品不良反应

Abstract: Objective To investigate the clinical characteristics, management strategies and outcomes of extremely severe thrombocytopenia induced by tirofiban. Methods One case of severe thrombocytopenia induced by tirofiban was analyzed, the correlation between thrombocytopenia and tirofiban was studied, and related literature was retrieved before the mechanisms underlying tirofiban-induced thrombocytopenia were investigated. Results Tirofiban was discontinued immediately after detection of the adverse reaction, followed by quick symptomatic treatment. Subsequent blood routine indices returned to normal, clinical parameters were stabilized, and the patient showed favorable recovery with a good prognosis. Conclusion Cases of extremely severe thrombocytopenia caused by tirofiban are relatively rare. Clinical pharmacists’ analysis of the treatment process can facilitate individualized medications in similar cases. It is recommended that clinicians monitor platelet counts while tirofiban is used and remain vigilant against adverse reactions.

Key words: Tirofiban, Injection, Bleeding, Thrombocytopenia, Percutaneous Coronary Interventions, Adverse Drug Reaction

中图分类号: